Mobilan is a nanoparticle-formulated, recombinant non-replicating adenovirus in clinical development as a universal cancer therapy.

In preclinical studies, delivery of Mobilan to tumor cells caused constant toll-like receptor 5 (TLR5) signaling that induced innate immune response to the tumor with subsequent development of adaptive immune response. An IND was opened in the Russian Federation for a Phase 1 multicenter, randomized, placebo-controlled, single-blinded study evaluating single injections of ascending doses of Mobilan administered directly into the prostate of patients with prostate cancer.

Panacela, our joint venture, holds worldwide development and commercialization rights to Mobilan.

You are now leaving this website. If you would like to continue, click Continue.